Watching local relapse after high-grade osteosarcoma treatment
Part of Cancer clinical trials.
This study is watching people whose high-grade osteosarcoma came back in the same bone area (local relapse) after treatment. It helps doctors understand how local relapse happens, so they can improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a high-grade osteosarcoma (a type of bone cancer) that came back in the same area (local recurrence) after initial treatment.
- The local recurrence was the first sign that the cancer returned (not spread to other parts of the body first).
- If you had lung spots when first diagnosed, you can still join.
- You are willing to come to follow-up visits and give permission to use your medical data.
- There is no age limit—anyone can take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the experiences of people with osteosarcoma who are taking part in clinical trials. By joining, you'll help researchers understand what it's like for patients, which may improve future care.
This trial focuses on improving how osteosarcoma care is coordinated and delivered, using collaboration between clinicians. It may help by helping teams make more consistent treatment decisions for people newly diagnosed.
This Phase 2 study tests whether regorafenib, given after your main treatments, can help keep high-grade bone sarcoma from coming back or progressing. It checks safety and whether this “maintenance” approach works better than best supportive care alone.
This trial tests whether combining an immunotherapy drug (atezolizumab) with focused radiation and surgery can help people whose osteosarcoma has come back only in the lungs. It aims to see if this approach is safe and may improve outcomes.
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
This trial studies whether regorafenib given after first treatment helps patients with bone sarcoma stay in remission longer. It focuses on safety and whether the medicine can prevent the cancer from growing or returning.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.